Mayo Clinic has launched a new type of blood test that will be used to predict adverse cardiovascular events in patients with progressing coronary artery disease (CAD). The test measures blood concentrations of plasma ceramides, a class of lipids that are highly linked to cardiovascular disease processes.
Researchers say this test is especially useful for patients with CAD when it does not improve with treatment or for young patients with premature CAD.
